Brussels, 4 March 2022. On this World Obesity Day, social, health and consumer organisations call on the EU to adopt strong regulation to protect children from the marketing of nutritionally poor food. Obesity is on the rise among European citizens,…
EASL and other health organisations wrote a joint press release with regards to the Parliamentary Report “Strengthening Europe in the fight against cancer” (BECA report). The health community is appalled that Members of European Parliament have listened to the alcohol industry rather than to scientists and public health experts.
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.
Alcohol-related Liver Disease (ARLD) is the major cause of liver disease in Europe and, since it depends mostly on harmful alcohol consumption, it is a highly preventable disease.
Full version of Policy Statement
The Best of ILC 2019 slide decks on Metabolism, alcohol and toxicity provides highlights of new data presented at the International Liver Congress™ 2019. The slide decks are supported by an unrestricted education grant from Boehringer Ingelheim and MSD. Boehringer…
Alcohol-related Liver Disease (ARLD) is the major cause of liver disease in Europe and, since it depends mostly on harmful alcohol consumption, it is a highly preventable disease.
Full version of Policy Statement
Prevalence of NAFLD continues to rise and is now becoming one of the most frequent causes of cirrhosis (advanced liver disease) and liver transplantation in Europe
Full version of Policy Statement
The focus of this EASL Guideline is idiosyncratic Drug-Induced Liver Injury (DILI). However, it is important to recognise that DILI is traditionally classified as intrinsic (or direct) vs. idiosyncratic. Intrinsic DILI is typically dose-related and occurs in a large proportion of individuals exposed to the drug (predictable) and onset is within a short time span (hours to days). Idiosyncratic DILI is usually not dose-related. Although a dose threshold of 50–100 mg/day is usually required. It occurs in only a small proportion of exposed individuals (unpredictable) and exhibits a variable latency to onset of days to weeks.
The harmful use of alcohol has been estimated to cause approximately 3.3 million deaths every year. Most importantly, this corresponds to nearly 6% of all deaths globally. Therefore, the effective treatment and Management of Alcohol-Related Liver Disease is a pertinent public health issue. In conclusion, the following EASL Clinical Practice Guideline reviews and provides the latest data on the treatment and Management of Alcohol-Related Liver Disease and updates recommendations for clinical management.
The Clinical Practice Guidelines propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference. The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities.